Hemay020
- Generic Name
- Hemay020
Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT02467569
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Centre, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath